Rights and permissions
About this article
Cite this article
Erlotinib, docetaxel better value than pemetrexed for NSCLC. Pharmacoecon. Outcomes News 644, 8 (2012). https://doi.org/10.2165/00151234-201206440-00021
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201206440-00021